The World Health Organization (WHO) listed in its “Priority Medicines Update Report for Europe and the World” launched on 9 July 2013, Chronic Obstructive Pulmonary Disease as a priority.
With the help of health experts, and commissioned by the European Commission, the WHO report identified “pharmaceutical gaps”: diseases of public health importance for which pharmaceutical treatments either do not exist or are inadequate.[photo: European Commission]
The report provides a public-health-based medicines development agenda, based on a systematic methodology for priority setting. National and European policies relevant to the European pharmaceutical and biotechnological industries will be influenced by the report’s recommendations. It will also provide important input to health-related policy development and research & innovation, including international cooperation.
The report is an update to the original 2004 Report Priority Medicines for Europe and the World and takes into account changes in global health and pharmaceutical innovation since 2004 in order to better address current and future patient needs.
In 2013 the European Commission requested that the report be updated as a resource to be used in planning the Horizon 2020 combined research programme for the European Union. The primary audience for the 2013 Update are the decision-makers working in the European Commission, Parliament, and Council who will be responsible for defining the Horizon 2020 Programme. (more…)